Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply

Published:2024-05-27 Issue:1 Volume:60 Page:107-108
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Burghart Lukas¹²^ORCID,Hofer Benedikt Silvester²³⁴^ORCID,Halilbasic Emina²³,Simbrunner Benedikt²³⁴^ORCID,Staettermayer Albert Friedrich²³⁴,Trauner Michael²³,Reiberger Thomas²³⁴^ORCID

Affiliation:

1. Klinik Ottakring, Wiener Gesundheitsverbund Vienna Austria

2. Rare Liver Diseases (RALID) Center of the ERN RARE‐LIVER at the Vienna General Hospital Vienna Austria

3. Division of Gastroenterology and Hepatology, Department of Medicine III Medical University of Vienna Vienna Austria

4. Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III Medical University of Vienna Vienna Austria

Abstract

LINKED CONTENTThis article is linked to Hofer et al papers. To view these articles, visit https://doi.org/10.1111/apt.17908 and https://doi.org/10.1111/apt.18044.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18067

Reference4 articles.

1. Letter: fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis;Ao X;Aliment Pharmacol Ther,2024

2. Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study

3. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis

4. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis